Kim M H, Koo T H, Sah W J, Chung S M
Department of Ophthalmology, Kangman St. Mary's Hospital, Seoul, Korea.
Ophthalmic Surg Lasers. 1998 Sep;29(9):762-6.
The purpose of this study is to investigate the efficacy of tissue plasminogen activator (tPA) in the treatment of total hyphema following ocular trauma or intraocular surgery. Three patients (3 eyes) representing unresolved total hyphema for more than 5 days and uncontrolled high intraocular pressure received intracameral injections of 10 microgram of recombinant tPA. Intracameral tPA injection resulted in complete resolution of hyphema in all 3 eyes. Resolution occurred mostly within 24 to 48 hours after injection. Possible side effects of tPA injection, such as increased intraocular pressure and corneal edema, were not observed. However, 1 eye had vitreous hemorrhage after repeated injections of tPA. Intracameral injection of tPA seems to be a safe and effective method for the treatment of unresolved total hyphema. However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.
本研究的目的是探讨组织型纤溶酶原激活剂（tPA）治疗眼外伤或眼内手术后全前房积血的疗效。3例（3眼）全前房积血持续5天以上且眼压控制不佳的患者接受了前房内注射10微克重组tPA。前房内注射tPA后，所有3眼的前房积血均完全消退。积血大多在注射后24至48小时内消退。未观察到tPA注射可能的副作用，如眼压升高和角膜水肿。然而，1眼在重复注射tPA后发生了玻璃体积血。前房内注射tPA似乎是治疗未消退全前房积血的一种安全有效的方法。然而，重复前房内注射tPA可能会引起如玻璃体积血等不良并发症。
